CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer

Shandong First Medical University

Status: Completed

Conditions: Small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT07316309

QHY04-LS-SCLC-01

Details and patient eligibility

About

This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC).

Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent [18F]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker.

The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.

Full description

This was a single-center, prospective observational study conducted at Shandong Cancer Hospital and Institute to investigate the prognostic value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC).

Eligible patients with histologically confirmed LS-SCLC underwent [18F]AlF-NOTA-QHY-04 PET/CT imaging prior to standard concurrent chemoradiotherapy. PET/CT parameters reflecting CXCR4 expression were measured and analyzed.

Patients were subsequently followed up according to routine clinical practice. Clinical outcomes, including progression-free survival and overall survival, were recorded during follow-up. The association between baseline CXCR4 PET/CT imaging findings and clinical outcomes was evaluated to explore the potential role of CXCR4-targeted PET/CT as a prognostic imaging biomarker in LS-SCLC.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histopathologically confirmed limited-stage small cell lung cancer (T1-4N0-3M0) according to the AJCC TNM 8th edition.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Presence of measurable disease according to RECIST version 1.1.
• Newly diagnosed patients who had not received any prior anticancer treatment.
• Underwent baseline [18F]AlF-NOTA-QHY-04 PET/CT imaging prior to treatment.

Exclusion criteria

• Presence of autoimmune diseases or active comorbid infections.
• Pregnancy or breastfeeding.
• Unable or unwilling to provide informed consent.

Trial design

33 participants in 1 patient group

Limited-Stage Small Cell Lung Cancer Cohort

Description:

Patients with histologically confirmed limited-stage small cell lung cancer who were enrolled prospectively and received standard-of-care treatment according to institutional protocols.